Almac to collaborate with Illumina on next-generation sequencing-based companion diagnostic development
The partnership with Illumina will provide an additional platform for the delivery of complex assays, expanding the options available to Almac partners
Almac Diagnostics, part of the Almac Group, is collaborating with Illumina to establish a framework for the development of next-generation sequencing (NGS)-based companion diagnostic assays.
The collaboration enables Almac to develop next-generation sequencing (NGS) assays using the Illumina MiSeqDx instrument, the first FDA-cleared IVD NGS system designed specifically for the clinical laboratory environment.
Almac offers significant expertise in the development and delivery of multiplex RNA and DNA based tests and currently partners with a number of major biopharmaceutical companies to assist with companion diagnostic development. The collaboration with Illumina serves to provide an additional platform for the delivery of complex assays, expanding the options available to Almac partners.
‘We are extremely pleased to announce this collaboration with Illumina. We are fully committed to the development of precision medicine and partnerships of this nature provide more avenues for test delivery, enabling the development of diagnostic tests that will ultimately improve care in a wide range of disease areas,’ said Professor Paul Harkin, President and Managing Director of Almac Diagnostics.
